AndroGel What to Expect: Week-by-Week First Month Guide
At a glance
- Label form / testosterone gel 1%, not the 1.62% gel [1]
- Starting dose, 1% gel / 50 mg once daily in the morning [1]
- Application sites / shoulders, upper arms and/or abdomen; not genitals, chest, armpits, knees or back [1]
- Shower or swim / avoid for at least 5 hours after application [1]
- Boxed warning / virilization reported in children secondarily exposed to testosterone gel [1]
- Monitoring / hematocrit before starting, at 3 to 6 months, then annually; other labs periodically [1]
- Week-by-week timeline / not in the 1% label; the T-Trials report results at 1 year [1][3]
Is There a Week-by-Week Timeline?
The 1% label gives no week 1 to week 4 schedule for energy, mood, libido or erections [1]. The T-Trials, described below, reported outcomes after 1 year of gel, and TRAVERSE after a mean of 21.7 months of treatment [3][4]. The 1% label says its dosing differs from testosterone gel 1.62%, which has its own prescribing information [1].What the 1% Label Covers
This page uses the label for generic testosterone gel 1%. Its starting dose is 50 mg once daily in the morning, applied to clean, dry, intact skin of the shoulders, upper arms and/or abdomen [1]. The label says not to apply the gel to the genitals, chest, armpits, knees or back [1]. It says to let the gel dry before dressing, wash hands thoroughly, and avoid fire, flames or smoking until the gel dries because alcohol-based gel is flammable, and to avoid swimming or showering for at least 5 hours after application [1].The boxed warning is secondary exposure: virilization has been reported in children exposed to testosterone gel, and children should avoid contact with unwashed or unclothed application sites [1].
What to Watch For
The label lists acne, application-site reaction, abnormal lab tests and prostatic disorders as the most common adverse reactions (incidence 5% or more) [1]. Its adverse event tables come from a 180-day trial and a 3-year extension, not from a first-month breakdown [1]. It warns that testosterone gel can raise blood pressure and is not recommended in uncontrolled hypertension; in an ambulatory blood pressure monitoring study of the 1% gel, mean systolic/diastolic pressure rose 1.9/1.3 mm Hg from baseline after 16 weeks [1]. Venous thromboembolism, edema and sleep apnea are also listed warnings [1].The label says check hematocrit before starting, re-evaluate at 3 to 6 months, then annually, and monitor serum testosterone, PSA, hemoglobin, hematocrit, liver function tests and lipids periodically [1]. The 1% label also warns that exogenous androgens may lead to azoospermia, and the Endocrine Society guideline recommends against starting testosterone in men planning fertility in the near term [1][2].
What Longer Studies Show
The T-Trials assigned 790 symptomatic men aged 65 or older with testosterone below 275 ng/dL to testosterone gel or placebo for 1 year [3]. Testosterone increased sexual activity, sexual desire and erectile function; it had no significant benefit for vitality, though men on testosterone reported slightly better mood and lower severity of depressive symptoms [3]. Results were reported at 1 year, not week by week.TRAVERSE randomized 5,246 men aged 45 to 80 with hypogonadism and cardiovascular disease or high risk to daily 1.62% testosterone gel or placebo [4]. Major adverse cardiovascular events occurred in 7.0% on testosterone and 7.3% on placebo; mean treatment was 21.7 months and follow-up 33 months [4]. Mean systolic pressure rose 1.0 mm Hg on testosterone versus a 0.5 mm Hg fall on placebo at 36 months [4].
Frequently asked questions
When will I feel testosterone gel working?
How is testosterone gel 1% applied?
Can I shower after applying it?
What blood tests does the label mention?
What is the boxed warning?
References
- U.S. National Library of Medicine, DailyMed. Testosterone gel 1% topical (generic, Actavis Pharma for Teva) prescribing information. Testosterone gel 1% topical (generic, Actavis Pharma for Teva) label
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
- Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-24. Effects of Testosterone Treatment in Older Men
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. Cardiovascular Safety of Testosterone-Replacement Therapy